Odyssey Therapeutics Reports Positive OD-001 Phase 2a UC Results
Odyssey Therapeutics, Inc. announced positive results from its Phase 2a monotherapy trial of OD-001 for ulcerative colitis, meeting the primary endpoint and showing a 27% clinical remission rate. The company also provided updates on its pipeline, including OD-002 (SLC15A4 inhibitor) with CTA filing expected in 2H 2026, and OD-003 (TNFR2 agonist) in IND-enabling studies. Odyssey reported a strong financial position with $464 million cash as of March 31, 2026, extending its operational runway into the second half of 2028.
Key Highlights
- OD-001 Phase 2a trial for ulcerative colitis met primary endpoint with -2.6 change in MMCS (p < 0.001).
- Clinical remission rate was 27%, with similar activity in AT-experienced patients.
- OD-001 demonstrated a promising safety profile, well-tolerated at 10 mg BID and 20 mg BID.
- OD-002 (SLC15A4 inhibitor) IND-enabling studies are ongoing, with CTA filing expected 2H 2026.
- OD-003 (TNFR2 agonist) IND-enabling studies are ongoing for autoimmune and inflammatory diseases.
- Company expects $464 million cash as of March 31, 2026, providing runway into 2H 2028.
Price Impact
More from ODTX
Odyssey Therapeutics Reports Q1 2026 Results; OD-001 Shows Positive Data
Odyssey Therapeutics Raises $288.7M from IPO; Q1 Net Loss $(38.26)M
Odyssey Therapeutics Reports Positive OD-001 Clinical Data; $464M Cash